310 related articles for article (PubMed ID: 29627234)
1. Nasal vaccination with r4M2e.HSP70c antigen encapsulated into N-trimethyl chitosan (TMC) nanoparticulate systems: Preparation and immunogenicity in a mouse model.
Dabaghian M; Latifi AM; Tebianian M; NajmiNejad H; Ebrahimi SM
Vaccine; 2018 May; 36(20):2886-2895. PubMed ID: 29627234
[TBL] [Abstract][Full Text] [Related]
2. A truncated C-terminal fragment of Mycobacterium tuberculosis HSP70 enhances cell-mediated immune response and longevity of the total IgG to influenza A virus M2e protein in mice.
Dabaghian M; Latifi AM; Tebianian M; Dabaghian F; Ebrahimi SM
Antiviral Res; 2015 Aug; 120():23-31. PubMed ID: 25989418
[TBL] [Abstract][Full Text] [Related]
3. Vaccination with recombinant 4 × M2e.HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens.
Dabaghian M; Latify AM; Tebianian M; Nili H; Ranjbar AR; Mirjalili A; Mohammadi M; Banihashemi R; Ebrahimi SM
Vet Microbiol; 2014 Nov; 174(1-2):116-26. PubMed ID: 25293397
[TBL] [Abstract][Full Text] [Related]
4. Conjugating influenza a (H1N1) antigen to n-trimethylaminoethylmethacrylate chitosan nanoparticles improves the immunogenicity of the antigen after nasal administration.
Liu Q; Zheng X; Zhang C; Shao X; Zhang X; Zhang Q; Jiang X
J Med Virol; 2015 Nov; 87(11):1807-15. PubMed ID: 25959372
[TBL] [Abstract][Full Text] [Related]
5. Development and characterization of chitosan coated poly-(ɛ-caprolactone) nanoparticulate system for effective immunization against influenza.
Gupta NK; Tomar P; Sharma V; Dixit VK
Vaccine; 2011 Nov; 29(48):9026-37. PubMed ID: 21939718
[TBL] [Abstract][Full Text] [Related]
6. Vaccination with three tandem repeats of M2 extracellular domain fused to Leismania major HSP70 protects mice against influenza A virus challenge.
Shokouhi H; Farahmand B; Ghaemi A; Mazaheri V; Fotouhi F
Virus Res; 2018 Jun; 251():40-46. PubMed ID: 29730305
[TBL] [Abstract][Full Text] [Related]
7. N-trimethyl chitosan (TMC) nanoparticles loaded with influenza subunit antigen for intranasal vaccination: biological properties and immunogenicity in a mouse model.
Amidi M; Romeijn SG; Verhoef JC; Junginger HE; Bungener L; Huckriede A; Crommelin DJ; Jiskoot W
Vaccine; 2007 Jan; 25(1):144-53. PubMed ID: 16973248
[TBL] [Abstract][Full Text] [Related]
8. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine.
Hagenaars N; Verheul RJ; Mooren I; de Jong PH; Mastrobattista E; Glansbeek HL; Heldens JG; van den Bosch H; Hennink WE; Jiskoot W
J Control Release; 2009 Dec; 140(2):126-33. PubMed ID: 19712713
[TBL] [Abstract][Full Text] [Related]
9. Nasal Administration of M2e/CpG-ODN Encapsulated in N-Trimethyl Chitosan (TMC) Significantly Increases Specific Immune Responses in a Mouse Model.
Taghizadeh M; Dabaghian M
Arch Razi Inst; 2022 Dec; 77(6):2259-2268. PubMed ID: 37274902
[TBL] [Abstract][Full Text] [Related]
10. In contrast to conventional inactivated influenza vaccines, 4xM2e.HSP70c fusion protein fully protected mice against lethal dose of H1, H3 and H9 influenza A isolates circulating in Iran.
Ebrahimi SM; Dabaghian M; Tebianian M; Jazi MH
Virology; 2012 Aug; 430(1):63-72. PubMed ID: 22595444
[TBL] [Abstract][Full Text] [Related]
11. Immunogenicity and protective efficacy of the norovirus P particle-M2e chimeric vaccine in chickens.
Elaish M; Kang KI; Xia M; Ali A; Shany SA; Wang L; Jiang X; Lee CW
Vaccine; 2015 Sep; 33(38):4901-9. PubMed ID: 26232342
[TBL] [Abstract][Full Text] [Related]
12. Simultaneous formulation of influenza vaccine and chitosan nanoparticles within CpG oligodesoxi nucleotides leads to dose-sparing and protects against lethal challenge in the mouse model.
Sadati SF; Jamali A; Abdoli A; Abedi-Valugerdi M; Gholami S; Alipour S; Soleymani S; Kheiri MT; Atyabi F
Pathog Dis; 2018 Nov; 76(8):. PubMed ID: 30184220
[TBL] [Abstract][Full Text] [Related]
13. Alkyl polyglycoside, a highly promising adjuvant in intranasal split influenza vaccines.
Wu H; Bao Y; Wang X; Zhou D; Wu W
Hum Vaccin Immunother; 2017 Jun; 13(6):1-9. PubMed ID: 28129034
[TBL] [Abstract][Full Text] [Related]
14. Development of a candidate influenza vaccine based on virus-like particles displaying influenza M2e peptide into the immunodominant region of hepatitis B core antigen: Broad protective efficacy of particles carrying four copies of M2e.
Tsybalova LM; Stepanova LA; Kuprianov VV; Blokhina EA; Potapchuk MV; Korotkov AV; Gorshkov AN; Kasyanenko MA; Ravin NV; Kiselev OI
Vaccine; 2015 Jun; 33(29):3398-406. PubMed ID: 25976545
[TBL] [Abstract][Full Text] [Related]
15. Dual role of CpG as immune modulator and physical crosslinker in ovalbumin loaded N-trimethyl chitosan (TMC) nanoparticles for nasal vaccination.
Slütter B; Jiskoot W
J Control Release; 2010 Nov; 148(1):117-121. PubMed ID: 20600405
[TBL] [Abstract][Full Text] [Related]
16. Immunization against HTLV-I with chitosan and tri-methylchitosan nanoparticles loaded with recombinant env23 and env13 antigens of envelope protein gp46.
Amirnasr M; Fallah Tafti T; Sankian M; Rezaei A; Tafaghodi M
Microb Pathog; 2016 Aug; 97():38-44. PubMed ID: 27235335
[TBL] [Abstract][Full Text] [Related]
17. A new adjuvanted nanoparticle-based H1N1 influenza vaccine induced antigen-specific local mucosal and systemic immune responses after administration into the lung.
Neuhaus V; Chichester JA; Ebensen T; Schwarz K; Hartman CE; Shoji Y; Guzmán CA; Yusibov V; Sewald K; Braun A
Vaccine; 2014 May; 32(26):3216-22. PubMed ID: 24731807
[TBL] [Abstract][Full Text] [Related]
18. Rabbit nasal immunization against influenza by dry-powder form of chitosan nanospheres encapsulated with influenza whole virus and adjuvants.
Dehghan S; Tafaghodi M; Bolourieh T; Mazaheri V; Torabi A; Abnous K; Tavassoti Kheiri M
Int J Pharm; 2014 Nov; 475(1-2):1-8. PubMed ID: 25148732
[TBL] [Abstract][Full Text] [Related]
19. Protection against influenza A virus by vaccination with a recombinant fusion protein linking influenza M2e to human serum albumin (HSA).
Mu X; Hu K; Shen M; Kong N; Fu C; Yan W; Wei A
J Virol Methods; 2016 Feb; 228():84-90. PubMed ID: 26615805
[TBL] [Abstract][Full Text] [Related]
20. Recombinant baculovirus vaccine containing multiple M2e and adjuvant LTB induces T cell dependent, cross-clade protection against H5N1 influenza virus in mice.
Zhang J; Fan HY; Zhang Z; Zhang J; Zhang J; Huang JN; Ye Y; Liao M
Vaccine; 2016 Jan; 34(5):622-629. PubMed ID: 26724200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
